More in-depth commentary regarding the potential benefits from using PTP1B inhibitors in causal treatment of neurodegenerative diseases such as AD, PD, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) was recently published by the authors [170]. The gene discussed is PTPN1; the disease is amyotrophic lateral sclerosis.